| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 18, 2008
Accepted on February 29, 2008
Program on Reproductive and Adult Endocrinology, NICHD, National Institutes of Health (L.K.N.), Bethesda, Maryland; Harvard Medical School/Massachusetts General Hospital (B.M.K.B.), Boston, Massachusetts; Medical College of Wisconsin (J.W.F.), Milwaukee, Wisconsin; University of Sheffield (J.N-P.), Sheffield, United Kingdom; Queen Mary University of London (M.O.S.), London, United Kingdom; University of Birmingham (P.M.S.), Birmingham, United Kingdom; and Mayo Clinic (V.M.M.), Rochester, Minnesota
* To whom correspondence should be addressed. E-mail: govt-prof{at}endo-society.org.
Objective: To develop clinical practice guidelines for the diagnosis of Cushing's syndrome.
Participants: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration.
Consensus Process: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a Web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments.
Conclusions: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in (a) patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and (b) patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1-mg overnight or 2-mg 48-hour dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with (a) discordant results, (b) normal responses suspected of cyclic hypercortisolism, or (c) initially normal responses who accumulate additional features over time.
This article has been cited by other articles:
![]() |
T. Deutschbein, N. Unger, J. Hinrichs, M. K Walz, K. Mann, and S. Petersenn Late-night and low-dose dexamethasone-suppressed cortisol in saliva and serum for the diagnosis of cortisol-secreting adrenal adenomas Eur. J. Endocrinol., November 1, 2009; 161(5): 747 - 753. [Abstract] [Full Text] [PDF] |
||||
![]() |
T J Cawood, P J Hunt, D O'Shea, D Cole, and S Soule Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur. J. Endocrinol., October 1, 2009; 161(4): 513 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Baid, D. Rubino, N. Sinaii, S. Ramsey, A. Frank, and L. K. Nieman Specificity of Screening Tests for Cushing's Syndrome in an Overweight and Obese Population J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3857 - 3864. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Raff Utility of Salivary Cortisol Measurements in Cushing's Syndrome and Adrenal Insufficiency J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3647 - 3655. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Veytsman, L. Nieman, and T. Fojo Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma J. Clin. Oncol., September 20, 2009; 27(27): 4619 - 4629. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Boscaro and G. Arnaldi Approach to the Patient with Possible Cushing's Syndrome J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3121 - 3131. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Wood Salivary steroids Ann Clin Biochem, September 1, 2009; 46(5): 427 - 427. [Full Text] [PDF] |
||||
![]() |
F. Castinetti, M. Nagai, I. Morange, H. Dufour, P. Caron, P. Chanson, C. Cortet-Rudelli, J.-M. Kuhn, B. Conte-Devolx, J. Regis, et al. Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3400 - 3407. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Chiodini, V. Morelli, B. Masserini, A. S. Salcuni, C. Eller-Vainicher, R. Viti, F. Coletti, G. Guglielmi, C. Battista, V. Carnevale, et al. Bone Mineral Density, Prevalence of Vertebral Fractures, and Bone Quality in Patients with Adrenal Incidentalomas with and without Subclinical Hypercortisolism: An Italian Multicenter Study J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3207 - 3214. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Arnaldi, G. Tirabassi, R. Papa, G. Furlani, L. Trementino, M. Cardinaletti, E. Faloia, and M. Boscaro Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing's disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis Eur. J. Endocrinol., June 1, 2009; 160(6): 891 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Castinetti, M. Martinie, I. Morange, H. Dufour, N. Sturm, J.-G. Passagia, B. Conte-Devolx, O. Chabre, and T. Brue A Combined Dexamethasone Desmopressin Test as an Early Marker of Postsurgical Recurrence in Cushing's Disease J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1897 - 1903. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Castinetti, M Fassnacht, S Johanssen, M Terzolo, P Bouchard, P Chanson, C Do Cao, I Morange, A Pico, S Ouzounian, et al. Merits and pitfalls of mifepristone in Cushing's syndrome Eur. J. Endocrinol., June 1, 2009; 160(6): 1003 - 1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Fagour, S. Bardet, V. Rohmer, Y. Arimone, P. Lecomte, N. Valli, and A. Tabarin Usefulness of adrenal scintigraphy in the follow-up of adrenocortical incidentalomas: a prospective multicenter study Eur. J. Endocrinol., February 1, 2009; 160(2): 257 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-L. Nunes, S. Vattaut, J.-B. Corcuff, A. Rault, H. Loiseau, B. Gatta, N. Valli, L. Letenneur, and A. Tabarin Late-Night Salivary Cortisol for Diagnosis of Overt and Subclinical Cushing's Syndrome in Hospitalized and Ambulatory Patients J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 456 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Carrasco, J. Coste, L. Guignat, L. Groussin, M. A. Dugue, S. Gaillard, X. Bertagna, and J. Bertherat Midnight Salivary Cortisol Determination for Assessing the Outcome of Transsphenoidal Surgery in Cushing's Disease J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4728 - 4734. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Reimondo, S. Bovio, B. Allasino, S. De Francia, B. Zaggia, I. Micossi, A. Termine, F. De Martino, P. Paccotti, F. Di Carlo, et al. The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing's syndrome Eur. J. Endocrinol., November 1, 2008; 159(5): 569 - 576. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |